CLL Responds to Induction With RCC Regimen Plus Rituximab Maintenance

CLL patients responded well to induction with the RCC regimen cladribine, cyclophosphamide, and rituximab followed by maintenance rituximab.

Source: CancerNetwork - February 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology Source Type: news